Gaston Geenslaan 1 , Heverlee, B-3001 Belgium
Phone: +32 (0) 16 75 13 10
ThromboGenics (Euronext Brussels: THR) is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer.
Our lead product, ocriplasmin (microplasmin), has completed two successful Phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). ThromboGenics will commercialize this product via its own dedicated sales force in the United States and in Europe.